P3 Health Partners Inc.
Close on Oct 19, 2026
- Market cap
- $12.81M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | $386.00M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | $386.00M | $0.32 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | After market close | $384.80M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | After market close | $345.30M | $-9.67 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $355.80M | $-6.23 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | $373.20M | $-6.28 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | After market close | $370.70M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $362.10M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on May 14, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDA (1)(3) (in millions)non-GAAP | Year Ending December 31, 2026 | $20.00M to $60.00M | New |
| At-risk Members | Year Ending December 31, 2026 | 103,000 to 110,000 | New |
| Medical Margin (1)(3) PMPMnon-GAAP | Year Ending December 31, 2026 | 149 to 180 | New |
| Medical Margin (1)(3) (in millions)non-GAAP | Year Ending December 31, 2026 | $190.00M to $230.00M | New |
| Total Revenues (in millions) | Year Ending December 31, 2026 | $1.50B to $1.65B | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements P3 Health Partners filed with the SEC
P3 Health Partners Announces Second Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
P3 HEALTH PARTNERS INC. and SUBSIDIARIES
Listing notice · Other events · EX-99.1 to Form 8-K
P3 Health Partners Announces First Quarter 2026 Results
Results of operations · EX-99 to Form 8-K
P3 Health Partners Announces Fourth Quarter and Full Year 2025 Results
Results of operations · EX-99.1 to Form 8-K
P3 Health Partners Announces Third Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
P3 Health Partners Announces Second Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
P3 Health Partners Announces First Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
P3 Health Partners Announces Fourth Quarter and Full Year 2024 Results
Results of operations · EX-99.1 to Form 8-K
P3 Health Partners Provides Preliminary 2025 Guidance and Announces Proposed Financing Transaction
Regulation FD disclosure · EX-99.1 to Form 8-K
P3 Health Partners Announces Third Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
P3 Health Partners Announces Second Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
P3 Health Partners Announces First Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
P3 Health Partners Announces Fourth Quarter and Full Year 2023 Results
Material agreement · Results of operations · New financial obligation · Other events · EX-99.1 to Form 8-K
P3 Health Partners Reaffirms Guidance for 2023 and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Other events · EX-99.1 to Form 8-K
P3 Health Partners Announces Third-Quarter and Year-to-Date 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
P3 Health Partners Announces Second-Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
P3 Health Partners Announces First-Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full-Year 2022 Results
Results of operations · EX-99.1 to Form 8-K
P3 Health Partners Affirms 2023 Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
P3 Health Partners Reaffirms Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Health Partners Provides Third-Quarter and Year-to-Date 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Provides Second-Quarter and Year-to-Date 2022
Results of operations · Executive or director change · EX-99.1 to Form 8-K
P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
P3 Health Partners Announces Receipt of Nasdaq Notice Regarding
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
P3 Health Partners Announces Receipt of Nasdaq Notice Regarding
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
P3 Health Partners to Present Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
P3 Health Partners Announces Select Preliminary
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Who: People with Passion and Purpose
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Who: People with Passion and Purpose
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AND NINE MONTHS ENDED SEPTEMBER 30, 2021 and 2020
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Closes Business Combination with Foresight Acquisition Corp. and Will Begin Trading on the Nasdaq
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K